Sanquin Blood Supply Foundation

Amsterdam, Netherlands

Sanquin Blood Supply Foundation

Amsterdam, Netherlands

Time filter

Source Type

Patent
Novo Nordisk AS and Sanquin Blood Supply Foundation | Date: 2016-11-18

The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.


de Kort W.,Sanquin Blood Supply Foundation
Transfusion | Year: 2014

The cost-effectiveness of the donor health questionnaire (DHQ) as a tool to assess donor eligibility has not been quantified. This study focused on cost-effectiveness of the DHQ in preventing transfusion-transmitted infections (TTIs). Data on whole blood donor eligibility assessments in the Netherlands in 2008 to 2010 were analyzed. Based on test results and epidemiologic data on TTIs, the number of donor visits in their window phase was calculated. Subsequently, the incremental cost-effectiveness ratio (ICER) of the DHQ was calculated. The overall annual deferral rate in the study period was 9.6% (9.3%-10.0%). The annual deferral rate for TTI risk was 0.86% (0.82%-0.89%). Taking into account the number of self-deferrals, deferral rate for TTI risk in all donors was 1.90% (1.81%-2.02%). The calculated annual numbers of prevented cases of TTI were hepatitis B, 0.142; hepatitis C, 0.010; human immunodeficiency virus, 0.016; and syphilis, 0.135. The annual costs for TTI risk-related eligibility assessments, deferrals, and substitutions were €84,807 (€55,193-€123,811) for the blood establishment (BE) and €90,501 (€46,965-€159,571) for deferred donors. Annual savings were €991 (€276-€2325), while annual quality-adjusted life-years (QALYs) gained were 0.120 (0.059-0.226). Hence, the ICER for the DHQ on preventing TTIs was €696,744 (€315,422-€1,611,681) for BE costs only and €1,449,055 (€669,439-€3,145,961) including costs for deferred donors. The DHQ enhances self-selection and should not be abandoned. However, the DHQ is not a cost-effective tool for further reducing TTIs. The high costs per case prevented and the small number of QALYs gained argue against maintaining deferral policy through the DHQ at the current level. © 2013 American Association of Blood Banks.


Lieshout-Krikke R.W.,Sanquin Blood Supply Foundation | Zaaijer H.L.,Sanquin Blood Supply Foundation | Van De Laar T.J.W.,Sanquin Blood Supply Foundation
Transfusion | Year: 2015

Background: Infectious window period donations slip through routine donor screening procedures. To explore the potential value of predonation screening of candidate donors, we compared the proportion of incident transfusion-transmissible infections in candidate donors, in first-time donors, and in repeat donors. Study Design and Methods: A retrospective analysis was performed of all incident hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections in candidate, first-time, and repeat donors in the Netherlands during the period 2009 to 2013. Results: In total, 176,716 candidate donors, 144,226 first-time donations, and 4,143,455 repeat donations were screened for HBV, HCV, and HIV infection. Acute HBV infection was identified in the predonation sample of six candidate donors. One first-time donor, testing HIV-negative at predonation screening, tested positive for anti-HIV and HIV RNA in the first donation 29 days later. Among repeat donations we identified 15, one, and six incident HBV, HCV and HIV infections, respectively. The proportion of incident infections among candidate donors/first-time donations/repeat donations was for HBV, 3.40/0/0.36; for HCV, 0/0/0.02; and for HIV 0/0.69/0.14 per 100,000, respectively. Conclusion: Predonation screening of candidate donors very likely causes a loss of donations, but it might prevent undetected window period donations. Further studies are necessary to determine the value of predonation screening as an additional safety measure. © 2014 AABB.


Lieshout-Krikke R.W.,Sanquin Blood Supply Foundation | Oei W.,University Utrecht | Habets K.,Sanquin Blood Supply Foundation | Pasker-De Jong P.C.M.,Sanquin Blood Supply Foundation
Transfusion | Year: 2015

Background Donors returning from areas with outbreaks of infectious diseases may donate infectious blood back home. Geographic donor deferral is an effective measure to ensure the blood safety, but donor deferral may pose a threat for the blood supply especially after holiday seasons. Insight into the travel behavior of blood donors is a first step to define appropriate deferral strategies. This study describes the travel behavior of Dutch donors, the actual deferral, and the consequences of deferral strategies on donor availability. Study Design and Methods A questionnaire designed to assess travel behavior (destination, frequency, and duration of travels) was sent to 2000 Dutch donors. The impact of travel deferral policies on donor availability was calculated, expressed as proportionate decrease in donor availability. The deferral policies considered were 1) deferral based on entire countries instead of affected regions where an infection is prevalent and 2) deferral after any travel outside Europe ("universal deferral"). Results Of the 1340 respondents, 790 (58.9%) donors traveled within Europe only, 61 (4.6%) outside Europe only, and 250 (18.7%) within and outside Europe. The deferral for entire countries and universal deferral would lead to 11.1 and 11.4% decrease in donor availability, respectively. Conclusion Most Dutch donors traveled outside the Netherlands, while 23.2% traveled outside Europe. Universal deferral resulted in an additional decrease in donor availability of 0.3% compared with deferral for entire countries instead of affected regions where an infection is prevalent. Thus, the universal deferral could be considered as a simpler and safer measure. © 2014 AABB.


Prinsze F.J.,Sanquin Blood Supply Foundation | Zaaijer H.L.,Sanquin Blood Supply Foundation
Vox Sanguinis | Year: 2012

Background and Objectives Blood donor screening reduces the infectious hazards related to blood transfusion, but the range of agents to be screened for is debatable. In 1993, the screening of all blood donations for Human T-Cell Lymphotropic virus (HTLV) was introduced in the Netherlands. We analysed the outcome and costs of HTLV donor screening. Methods For the years 2001-2010, the number of HTLV infections among new and regular donors was used to estimate the prevented number of HTLV-infected donors in the donor pool and the amount of morbidity prevented among recipients. Results Human T-Cell Lymphotropic virus screening in the Netherlands detects per year on average 1·4 infected new donors and 0·5 infected regular donors. The prevalence among new donors is 30 times higher than the incidence among regular donors. Without HTLV screening, 14 HTLV-infected donors would be donating blood, causing 0·8 to 0·007 cases of HTLV disease per year. Conclusion The lack of accurate estimators for infectivity and pathogenicity hampers the estimation of morbidity and mortality that HTLV-infected transfusions would cause. Leucodepletion may be as effective as HTLV donor screening; its effect on HTLV transmission should be studied. © 2011 The Author(s). Vox Sanguinis © 2011 International Society of Blood Transfusion.


Aalberse R.C.,Sanquin Blood Supply Foundation
Chemical Immunology and Allergy | Year: 2014

Historically, horse dandruff was a favorite allergen source material. Today, however, allergic symptoms due to airborne mammalian allergens are mostly a result of indoor exposure, be it at home, at work or even at school. The relevance of mammalian allergens in relation to the allergenic activity of house dust extract is briefly discussed in the historical context of two other proposed sources of house dust allergenic activity: mites and Maillard-type lysine-sugar conjugates. Mammalian proteins involved in allergic reactions to airborne dust are largely found in only 2 protein families: lipocalins and secretoglobins (Fel d 1-like proteins), with a relatively minor contribution of serum albumins, cystatins and latherins. Both the lipocalin and the secretoglobin family are very complex. In some instances this results in a blurred separation between important and less important allergenic family members. The past 50 years have provided us with much detailed information on the genomic organization and protein structure of many of these allergens. However, the complex family relations, combined with the wide range of post-translational enzymatic and non-enzymatic modifications, make a proper qualitative and quantitative description of the important mammalian indoor airborne allergens still a significant proteomic challenge. © 2014 S. Karger AG, Basel.


Slot E.,Sanquin Blood Supply Foundation | Hogema B.M.,Sanquin Blood Supply Foundation | Riezebos-Brilman A.,University of Groningen | Kok T.M.,Sanquin Blood Supply Foundation | And 2 more authors.
Eurosurveillance | Year: 2013

In Europe, the dynamics of endemic hepatitis E virus (HEV) infection remain enigmatic. We studied the presence of silent HEV infection among Dutch blood donors. Using donations collected throughout the Netherlands in 2011 and 2012, 40,176 donations were tested for HEV RNA in 459 pools of 48 or 480 donations. Deconstruction of the reactive pools identified 13 viraemic donors. In addition, 5,239 donors were tested for presence of anti-HEV IgG and IgM and for HEV RNA when IgM-positive. Of the 5,239 donations, 1,401 (27%) tested repeat-positive for HEV IgG, of which 49 (3.5%) also tested positive for anti-HEV IgM. Four of the HEV IgM-positive donors tested positive for HEV RNA. HEV IgG seroprevalence ranged from 13% among donors younger than 30 years to 43% in donors older than 60 years. The finding of 17 HEV RNA-positive donations among 45,415 donations corresponds to one HEV-positive blood donation per day in the Netherlands. For 16 of the 17 HEV RNA-positive donors, genotyping succeeded, revealing HEV genotype 3, which is circulating among Dutch pigs. Apparently, silent HEV infection is common in the Netherlands, which possibly applies to larger parts of Europe.


Kitchen S.,Royal Hallamshire Hospital | Gray E.,UK National Institute for Biological Standards and Control | Mertens K.,Sanquin Blood Supply Foundation
Haemophilia | Year: 2014

The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents. © 2014 John Wiley & Sons Ltd.


Patent
Novo Nordisk AS and Sanquin Blood Supply Foundation | Date: 2015-09-23

The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.


NIJMEGEN & AMSTERDAM, the Netherlands--(BUSINESS WIRE)--Synthon Biopharmaceuticals BV, an international biopharmaceutical company that is focused on developing new molecular entities for treating cancer and autoimmune diseases, today announced that it has entered a license and collaboration agreement for the development of novel immuno-oncology antibodies with Sanquin Blood Supply Foundation (‘Sanquin’), Amsterdam. Under the terms of the agreement, Synthon has obtained worldwide exclusive rights to Sanquin’s know-how, lead antibodies and intellectual property regarding the CD47-SIRPα pathway to develop new immuno-oncology treatments. CD47 is a broadly expressed membrane protein that interacts with the myeloid inhibitory immunoreceptor SIRPα (also termed CD172a or SHPS-1). When SIRPα engages with CD47, it provides a downregulatory signal that inhibits host cell phagocytosis, and CD47 therefore acts as a “don't-eat-me” signal. Blocking CD47-SIRPα interactions promotes the destruction of, for example, cancer cells by phagocytes through antibody-dependent mechanisms. Dr. Marco Timmers, chief scientific officer of Synthon Biopharmaceuticals commented: “We are particularly pleased with this license and collaboration agreement, which combines Sanquin’s outstanding research capabilities with Synthon’s biopharmaceutical drug development and manufacturing excellence. This will enable us to accelerate the availability of important new therapeutic treatment options for cancer patients who may benefit from these.” Prof. Dr. René van Lier, director of Research and Member of the Executive Board at Sanquin: "The collaboration agreement with Synthon, with their knowledge of next-generation medicines, is a great example of Sanquin's efforts to provide patients with innovative therapeutic treatment options." Financial details of the agreement were not disclosed. Sanquin is responsible for the blood supply in the Netherlands on a not-for-profit basis. Hundreds of thousands of non-remunerated blood donors make this possible. They are the heart of the organization. The core activity is safe and efficient production and distribution of blood and plasma products for the treatment of patients. Sanquin conducts scientific research, adding to our knowledge of blood and transfusion medicine. This enables Sanquin to advise hospitals and anyone treating patients. http://www.sanquin.nl/en/research/ Synthon, with headquarters in Nijmegen, the Netherlands, is an international pharmaceutical company and a leader in the field of generic medicines. The company started its biopharmaceutical franchise in 2007 and is building a promising portfolio of innovative next-generation medicines. Synthon is developing into a specialty pharmaceutical company, focusing on the therapeutic areas of oncology and auto-immune diseases. Synthon products are currently approved by regulatory agencies in around 100 countries worldwide and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon employs about 1,900 staff worldwide, and in 2016 it recorded a turnover of EUR 258 million. For more information, go to www.synthonbiopharmaceuticals.com

Loading Sanquin Blood Supply Foundation collaborators
Loading Sanquin Blood Supply Foundation collaborators